u/BlackberryThese4801

​

Star sem 27 let in ko hodim po stopnicah mi pokajo oz. škripajo kolenski sklep in gležnji. Je to nevarno? Nič me ne boli.

​

I'm not a cardiologist, so much of it flew over my head, but I managed to find some media coverage for two new trials presented during the cardiology conference last week, and I think they're definitely worth mentioning.

In the first trial, researchers examined the outcomes of people with type 2 diabetes undergoing PCI, which is essentially an angioplasty procedure designed to reopen blocked coronary arteries. Using real-world data, they compared the incidence of deaths and cardiovascular events between patients taking tirzepatide and dulaglutide (Trulicity), respectively. The results showed that patients receiving tirzepatide had a significantly reduced risk of death within one year, by 62%, and major cardiovascular events, by 54%. In the second trial, researchers focused on the safety profile of people with obesity undergoing TAVR, which is yet another cardiovascular surgery procedure. Patients not on tirzepatide had a significantly increased risk of adverse events, by 44%, and heart failure hospitalizations, by 54%.

However, since these studies are not controlled experiments but observational studies, this must be taken into account. In observational studies, causation cannot be established; associations can only be found between the factors studied. However, the effect size is quite substantial, and the results are supported by other real-world evidence. The death of my father due to a heart attack at age 62 makes such information especially memorable for me. This is why I continue taking these drugs despite the unchanging reading on the scales. Losing weight is wonderful, yet protecting myself from a heart attack could save my life someday.